Windtree Therapeutics, Inc. (formerly known as Discovery Laboratories, Inc.), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is pleased to announce the pricing of its public offering of 3,686,006 shares of common stock and warrants to purchase up to 3,686,006 shares of common stock.
Each share of common stock and accompanying warrant is being sold at a combined public offering price of $2.93, with the warrants exercisable immediately and expiring five years from the date of issuance. The Offering is expected to close on or about April 24, 2023, subject to the satisfaction of customary closing conditions.
Ladenburg Thalmann & Co. Inc. is proud to serve as the sole book running manager for this exciting Offering! They are eager to provide their expertise and assistance to ensure a successful outcome.
The Company has also granted the underwriter a 45-day option to purchase an additional 552,900 shares of common stock and/or warrants, at the public offering price discounted by the underwriting discounts and commissions. This means the underwriter has the potential to acquire a total of 1,105,800 shares and/or warrants upon exercising the option.
The Company is offering an opportunity for investors to join them in their journey to success with the Offering, which is expected to generate gross proceeds of approximately $10.8 million before deducting underwriting discounts and commissions and other expenses.
Up to $3.5 million of the net proceeds of the Offering will be used to extend enrollment and complete a Phase 2 clinical trial for istaroxime in cardiogenic shock, and the remainder will be used for working capital and other general corporate purposes. Invest now and be part of the Company’s future growth!
Windtree is offering securities pursuant to its registration statement on Form S-1 (File No. 333-269775) declared effective by the Securities and Exchange Commission (the “SEC”) on April 19, 2023 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b). To find out more, you can access the preliminary prospectus describing the terms of the Offering on the SEC’s website.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is on a mission to develop groundbreaking interventions to treat cardiovascular disorders in moments of crisis. From istaroxime, a first-in-class treatment for acute heart failure and cardiogenic shock, to follow-on SERCA2a activator assets and the transfer of the KL4 surfactant platform, Windtree is revolutionizing cardiovascular care.
Additionally, they are developing rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles. Together, these advancements are paving the way for a multi-asset franchise that will have a lasting impact on patients’ lives.